Waiting for the verdict
All eyes will be on Celltech as the London Stock Exchange opens for business on Monday, the first day it will trade as a FTSE 100 company. The LSE was closed when an FDA advisory committee on Friday recommended a limited label for CCH's Mylotarg gemtuzumab zogamicin in acute myeloid leukemia (AML), which was presented to the panel by partner Wyeth-Ayerst. Rumors that the product had been rejected prompted a halt in trading of the company's ADRs on the New York Stock Exchange at $36.375, down $4.125 on the day. CCH closed Friday at 1307.5p, up 72.5p on the day, but down 470p on the week at a market cap of £10.4 billion ($16.4 billion). (see Regulation, A6).
AdProTech raised £5 million ($7.9 million) in a second funding round. The autoimmune and inflammation company will use the funds to move APT070, a